Table 1.
Baseline characteristics of 291 patients at the time of completing the MISS
| Characteristic | Value in patient sample |
|---|---|
| Sex, female |
181 (62.2) |
| Age, mean +/- SD years |
59.4 +/- 12.4 |
| Diagnosis |
|
| Rheumatoid arthritis |
249 (85.6) |
| Psoriatic arthritis |
42 (14.4) |
| Disease activity |
|
| Disease activity score 28, median (IQR)a |
2.5 (1.7 to 3.2) |
| Physician’s global assessment, median (IQR), (0 to 10 scale)b |
2.0 (1.0 to 3.0) |
| Erythrocyte sedimentation rate (mm/hour) |
11.0 (5.0 to 22.0) |
| MTX use |
|
| Route of administration, oral |
194 (66.7) |
| Dose, mg/week, median (IQR) |
20.0 (12.5 to 25.0) |
| Other medication |
|
| NSAIDs |
145 (49.9) |
| Proton-pump inhibitors |
127 (43.6) |
| Anti-emetics |
5 (1.7) |
| Oral steroids |
31 (10.7) |
| Other DMARDsc | 72 (24.7) |
Characteristics are as calculated at the time of completing the MISS except where indicated otherwise. Values are number (%), except where indicated otherwise. aDisease activity score 28 was determined in 266 patients (274 rheumatoid arthritis and 19 psoriatic arthritis patients); bphysician’s global assessment was determined in 268 patients; cof 72 patients on other DMARDs, 26 were on DMARDs (plaquenil, n = 24; leflunomide, n = 2) and 46 were on biologic agents (infliximab, n = 24; adalimumab, n = 10; etanercept, n = 9; abatecept, n = 2; golimumab, n = 1). MISS, methotrexate intolerance severity score; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; DMARDs, disease-modifying anti-rheumatic drugs.